eligibility_summary
Adults 18-75 with CLDN18.2-positive (≥10%) solid tumors (e.g., gastric/GEJ or pancreatic adenocarcinoma) after ≥1 prior systemic therapy, ECOG 0-1, life expectancy >3 months, measurable disease, suitable for leukapheresis, adequate organ function. Exclude pregnancy/lactation, active infections (HBV/HCV/HIV), CNS mets, prior cell therapy, significant cardiac/thyroid/autoimmune disease, recent major VTE/surgery, bleeding risk, second cancers, allergy to conditioning.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Dual-targeting CLDN18.2/PD‑L1 CAR‑T cells (autologous, gene‑engineered T‑cell therapy). Mechanism: CARs enable T cells to bind CLDN18.2 on tumor cells, triggering antigen‑specific activation and cytolytic killing. Concurrent PD‑L1 targeting allows recognition/elimination of PD‑L1+ tumor and stromal cells and functionally counters PD‑1/PD‑L1–mediated immunosuppression, aiming to improve efficacy and reduce antigen escape. Targets/pathways: CLDN18.2 (tight-junction protein, enriched in gastric/GEJ and pancreatic cancers), PD‑L1 immune checkpoint axis, and T‑cell activation/cytotoxic pathways in the tumor microenvironment.